CMMB (Chemomab Therapeutics) EV-to-OCF: (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMMB Chemomab Therapeutics Ltd CMMB
34 GF Score
Price $1.53
View Full Analysis

What is Chemomab Therapeutics EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Chemomab Therapeutics's Enterprise Value is $0.85 Mil. Chemomab Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil. Therefore, Chemomab Therapeutics's EV-to-OCF for today is .

The historical rank and industry rank for Chemomab Therapeutics's EV-to-OCF or its related term are showing as below:

CMMB' s EV-to-OCF Range Over the Past 10 Years
Min: -0.12   Med: 0   Max: -0.03
Current: -0.08

During the past 6 years, the highest EV-to-OCF of Chemomab Therapeutics was -0.03. The lowest was -0.12. And the median was .

CMMB's EV-to-OCF is ranked worse than
71.21% of 1410 companies
in the Biotechnology industry
Industry Median: -3.2 vs CMMB: -0.08

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-30), Chemomab Therapeutics's stock price is $1.53. Chemomab Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.120. Therefore, Chemomab Therapeutics's PE Ratio (TTM) for today is At Loss.


Chemomab Therapeutics  (NAS:CMMB) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Chemomab Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.53/-1.120
=At Loss

Chemomab Therapeutics's share price for today is $1.53.
Chemomab Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Chemomab Therapeutics EV-to-OCF Related Terms


Chemomab Therapeutics EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Chemomab Therapeutics's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics EV-to-OCF Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-OCF
Get a 7-Day Free Trial -1.44 0.21 0.51 -1.31 -0.13

Chemomab Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.13 0.00

CMMB vs TOVX, BIVI, CRIS: EV-to-OCF Comparison

For the Biotechnology subindustry, Chemomab Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemomab Therapeutics EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's EV-to-OCF falls into.


CMMB
34GF Score
Chemomab Therapeutics Ltd CMMB
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemomab Therapeutics EV-to-OCF Calculation

Chemomab Therapeutics's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=0.845/0
=

Chemomab Therapeutics's current Enterprise Value is $0.85 Mil.
Chemomab Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chemomab Therapeutics Business Description

Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
34GF Score

Get the complete analysis for CMMB

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.53
Price